Brain, Vol. 124, No. 12, 2448-2458,
December 2001
© 2001 Oxford University Press
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor
1 Departments of Pathology and 2 Neurology, Hirosaki University School of Medicine, Hirosaki, 3 Department of Pharmacology, Kyoto Prefecture University of Medicine, Kyoto, 4 Department of Pathology, Sapporo Medical University of Medicine, Sapporo, Japan and 5 Global Business Management, Pharmacia, Peapack, New Jersey, USA
Correspondence to:
Dr Soroku Yagihashi, Department of Pathology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036–8562, Japan E-mail: yagihasi{at}cc.hirosaki-u.ac.jp
The present study was designed to examine the effect of aldose reductase (AR) overexpression on the development of diabetic neuropathy by using mice transgenic for human AR. At 8 weeks of age, transgenic mice (Tg) and non-transgenic littermates (Lm) were made diabetic with streptozotocin. After 8 weeks of untreated diabetes, plasma glucose levels and the reduction in body weight were similar between the groups of diabetic animals. Despite the comparable levels of hyperglycaemia, levels of sorbitol and fructose were significantly greater in the peripheral nerve of diabetic Tg than in diabetic Lm (both P < 0.01). Ouabain sensitive Na+,K+-ATPase activity was similarly decreased in both diabetic Tg and Lm. Protein kinase C activity in the sciatic nerve membrane fraction was unaffected by diabetes in Lm, but was reduced by nearly 40% in the diabetic Tg. Although both groups of diabetic animals exhibited a significant decrease in tibial nerve motor nerve conduction velocity (MNCV), this decrease was significantly more severe (P < 0.01) in diabetic Tg than in diabetic Lm. Consistent with these findings, nerve fibre atrophy was significantly more severe in diabetic Tg than in diabetic Lm (P < 0.01). These findings implicate increased polyol pathway activity in the pathogenesis of diabetic neuropathy. In support of this hypothesis, treating diabetic Tg with an aldose reductase inhibitor (WAY121-509, 4 mg/kg/day) for 8 weeks significantly prevented the accumulation of sorbitol, the decrease in MNCV and the increased myelinated fibre atrophy in diabetic Tg.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Baba, O. A. Barski, Y. Ahmed, T. E. O'Toole, D. J. Conklin, A. Bhatnagar, and S. Srivastava Reductive Metabolism of AGE Precursors: A Metabolic Route for Preventing AGE Accumulation in Cardiovascular Tissue Diabetes, November 1, 2009; 58(11): 2486 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Askwith, W. Zeng, M. C. Eggo, and M. J. Stevens Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E620 - E628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kabututu, M. Manin, J.-C. Pointud, T. Maruyama, N. Nagata, S. Lambert, A.-M. Lefrancois-Martinez, A. Martinez, and Y. Urade Prostaglandin F2{alpha} Synthase Activities of Aldo-Keto Reductase 1B1, 1B3 and 1B7 J. Biochem., February 1, 2009; 145(2): 161 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Kellogg, T. D. Wiggin, D. D. Larkin, J. M. Hayes, M. J. Stevens, and R. Pop-Busui Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes Diabetes, December 1, 2007; 56(12): 2997 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov, I. A. Pavlov, N. Mashtalir, J. L. Nadler, and V. R. Drel High-Fat Diet Induced Neuropathy of Pre-Diabetes and Obesity: Effects of "Healthy" Diet and Aldose Reductase Inhibition Diabetes, October 1, 2007; 56(10): 2598 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Goldberg and H. M. Dansky Diabetic Vascular Disease: An Experimental Objective Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1693 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C.M. Ho, K. S.L. Lam, Y. S. Chen, J. C.W. Yip, M. Arvindakshan, S.-I. Yamagishi, S. Yagihashi, P. J. Oates, C. A. Ellery, S. S.M. Chung, et al. Aldose Reductase-Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage. Diabetes, July 1, 2006; 55(7): 1946 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Misawa, S. Kuwabara, K. Kanai, N. Tamura, M. Nakata, S. Sawai, K. Yagui, and T. Hattori Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics Neurology, May 23, 2006; 66(10): 1545 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes, May 1, 2006; 55(5): 1478 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Chen, S. S.M. Chung, and S. K. Chung Noninvasive Monitoring of Diabetes-Induced Cutaneous Nerve Fiber Loss and Hypoalgesia in thy1-YFP Transgenic Mice Diabetes, November 1, 2005; 54(11): 3112 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Srivastava, K. V. Ramana, and A. Bhatnagar Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options Endocr. Rev., May 1, 2005; 26(3): 380 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Uehara, S.-I. Yamagishi, S. Otsuki, S. Chin, and S. Yagihashi Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice Diabetes, December 1, 2004; 53(12): 3239 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sigaudo-Roussel, C. Demiot, B. Fromy, A. Koitka, G. Leftheriotis, P. Abraham, and J. L. Saumet Early Endothelial Dysfunction Severely Impairs Skin Blood Flow Response to Local Pressure Application in Streptozotocin-Induced Diabetic Mice Diabetes, June 1, 2004; 53(6): 1564 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Obrosova, F. Li, O. I. Abatan, M. A. Forsell, K. Komjati, P. Pacher, C. Szabo, and M. J. Stevens Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic Neuropathy Diabetes, March 1, 2004; 53(3): 711 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Mizisin Comparative Neuropathology and Diabetic Autonomic Neuropathy Am. J. Pathol., November 1, 2003; 163(5): 1703 - 1706. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S.M. Chung, E. C.M. Ho, K. S.L. Lam, and S. K. Chung Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S233 - 236. [Abstract] [Full Text] [PDF]
|
|